DaVita Inc. (DVA)
NYQ – Real Time Price. Currency in USD
200.54
+1.61 (0.81%)
At close: May 12, 2026, 4:00 PM EDT
200.40
-0.14 (-0.07%)
After-hours: May 12, 2026, 7:47 PM EDT
Find any stock by ticker or company name

NYQ – Real Time Price. Currency in USD
200.54
+1.61 (0.81%)
At close: May 12, 2026, 4:00 PM EDT
200.40
-0.14 (-0.07%)
After-hours: May 12, 2026, 7:47 PM EDT
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
| Name | Position |
|---|---|
| Dr. Jeffrey Allen Giullian | Chief Medical Officer of Kidney Care |
| Dr. Partha Das M.D., M.Sc. | Chief Medical Officer of DaVita International |
| Mr. David P. Maughan | Chief Operating Officer of DaVita Kidney Care |
| Mr. James O. Hearty | Chief Compliance Officer |
| Mr. Javier J. Rodriguez | CEO & Executive Director |
| Mr. Joel Ackerman | CFO & Treasurer |
| Mr. Misha Palecek | Chief Transformation Officer of U.S. Kidney Care Business |
| Ms. Kathleen Alyce Waters | Chief Legal & Public Affairs Officer |
| Ms. Stephanie Hendrickson | Chief People Officer |
| Nic Eliason | Group Vice President of Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 10-Q | dva-20260331.htm |
| 2026-04-22 | DEF 14A | dva-20260422.htm |
| 2026-02-11 | 10-K | dva-20251231.htm |
| 2026-02-02 | 8-K | dva-20260202.htm |
| 2025-11-25 | 8-K | dva4564821-8k.htm |
| 2025-10-29 | 10-Q | dva-20250930.htm |
| 2025-08-20 | 8-K | dva-20250820.htm |
| 2025-08-05 | 8-K | dva-20250805.htm |
| 2025-08-05 | 10-Q | dva-20250630.htm |
| 2025-07-17 | 8-K | d75954d8k.htm |